Drug Trial Radar · NCT07690371
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
510
Planned (sponsor's estimate)
Start
Jun 29, 2026
Primary completion
May 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Nektar TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approximately 15 months.
Conditions
- Moderate-to-Severe Atopic Dermatitis
Interventions
RezpegaldesleukinDrug
Pharmaceutical form: Injection solution Route of administration: subcutaneous
PlaceboDrug
Pharmaceutical form: Injection solution Route of administration: subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24Time frame: Week 0 and Week 24
- Non-US regions only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 at Week 24Time frame: Week 0 and Week 24
- Non-US regions only: Number of participants with a ≥ 75% reduction in Eczema Area and Severity Index (EASI) score from baseline at Week 24 (EASI-75)Time frame: Week 0 and Week 24
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Nektar Investigative Site
Phoenix, Arizona · Recruiting
Nektar Investigative Site
North Little Rock, Arkansas · Recruiting
Nektar Investigative Site
Fountain Valley, California · Recruiting
Nektar Investigative Site
Los Angeles, California · Recruiting
Nektar Investigative Site
Boca Raton, Florida · Recruiting
Nektar Investigative Site
St. Petersburg, Florida · Recruiting
Nektar Investigative Site
Tampa, Florida · Recruiting
Nektar Investigative Site
Macon, Georgia · Recruiting
Nektar Investigative Site
Boise, Idaho · Recruiting
Nektar Investigative Site
Normal, Illinois · Recruiting
Nektar Investigative Site
Bowling Green, Kentucky · Recruiting
Nektar Investigative Site
Owensboro, Kentucky · Recruiting
Nektar Investigative Site
Lafayette, Louisiana · Recruiting
Nektar Investigative Site
Auburn Hills, Michigan · Recruiting
Nektar Investigative Site
Omaha, Nebraska · Recruiting
Nektar Investigative Site
Clifton, New Jersey · Recruiting
Nektar Investigative Site
New York, New York · Recruiting
Nektar Investigative Site
New York, New York · Recruiting
Nektar Investigative Site
Wilmington, North Carolina · Recruiting
Nektar Investigative Site
Oklahoma City, Oklahoma · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.